Evidence map›Paper›PMID 39352622›Full record

ArticleInternational journal of clinical oncology2024

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor.

Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, Takafumi Minami, Wataru Fukuokaya, Takafumi Yanagisawa, Masanobu Saruta, Kiyoshi Takahara, Kazuki Nishimura, Takuya Tsujino and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yutaka YamamotoDepartment of Urology, Kindai University, Nara Hospital, 1248-1 Otodacho, Ikoma, Nara, 630-0293, Japan. yamamotokindai@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7555-6295
Saizo FujimotoDepartment of Urology, Kindai University Hospital, Osaka, Japan.
Mamoru HashimotoDepartment of Urology, Kindai University Hospital, Osaka, Japan.
Takafumi MinamiDepartment of Urology, Kindai University Hospital, Osaka, Japan.
Wataru FukuokayaDepartment of Urology, The Jikei University Hospital, Tokyo, Japan.
Takafumi YanagisawaDepartment of Urology, The Jikei University Hospital, Tokyo, Japan.
Masanobu SarutaDepartment of Urology, Fujita Health University Hospital, Aichi, Japan.
Kiyoshi TakaharaDepartment of Urology, Fujita Health University Hospital, Aichi, Japan.
Kazuki NishimuraDepartment of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Takuya TsujinoDepartment of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Yuta NakamoriDepartment of Urology, Tokyo Medical University Hospital, Tokyo, Japan.
Takeshi HashimotoDepartment of Urology, Tokyo Medical University Hospital, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University Hospital, Tokyo, Japan.
Ryoichi ShirokiDepartment of Urology, Fujita Health University Hospital, Aichi, Japan.
Haruhito AzumaDepartment of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Yoshio OhnoDepartment of Urology, Tokyo Medical University Hospital, Tokyo, Japan.
Kazutoshi FujitaDepartment of Urology, Kindai University Hospital, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUpfront androgen receptor signaling inhibitor (ARSI) along with androgen deprivation therapy is the current standard of care for metastatic castration-sensitive prostate cancer. However, evidence on second-line therapy after upfront ARSI is scarce. We aimed to evaluate the oncological outcome of ARSI versus docetaxel (DOC) after upfront ARSI therapy in a real-world clinical practice.

methodsSubjects were metastatic castration-resistant prostate cancer (mCRPC) patients who had progressed within 2 years of upfront ARSI therapy and received ARSI (ARSI group) or DOC (DOC group) as a second-line therapy. Second-line progression-free survival (second-line PFS), and second-line overall survival (second-line OS) were assessed. Propensity score matching (PSM) was used to adjust the clinicopathological features and treatment patterns.

resultsA total of 101 mCRPC patients, 68 in the ARSI group, and 33 in the DOC group, were included in this analysis. Median second-line PFS was 6.3 months in the ARSI group and 4.9 months in the DOC group (p = 0.21). Median second-line OS was 25.0 months in the ARSI group and 14.2 months in the DOC group (p = 0.06). Prostate-specific antigen nadir ≤ 0.2 ng/ml during upfront ARSI therapy was significantly associated with improved second-line PFS. After PSM, no significant difference in second-line PFS and second-line OS were observed between the two groups.

conclusionARSI or DOC has comparable oncologic outcomes in terms of second-line PFS and second-line OS. Further prospective research with longer follow-ups will be needed to identify the optimal treatment after upfront ARSI therapy.

Indexed as

Androgen Receptor AntagonistsDocetaxelProgression-Free SurvivalProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overDisease ProgressionHumansMaleMiddle AgedReceptors, AndrogenRetrospective StudiesTreatment OutcomeAndrogen Receptor AntagonistsDocetaxelReceptors, AndrogenAndrogen receptor signaling inhibitorDocetaxelMetastatic castration-sensitive prostate cancerUpfront

Identifiers

PMID39352622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.